Hypersensitivity reactions to proton-pump inhibitors: Clinical presentation, diagnosis, and management

2020 ◽  
Vol 41 (2) ◽  
pp. e37-e44 ◽  
Author(s):  
Seçil Kepil Özdemir ◽  
Sevim Bavbek
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Clinical Presentation ◽  
Current Knowledge ◽  
Cross Reactivity ◽  
Delayed Hypersensitivity ◽  
Stevens Johnson Syndrome ◽  
Hypersensitivity Reactions ◽  
Fixed Drug Eruption ◽  
Maculopapular Eruption

Background: Proton-pump inhibitors (PPI) are one of the most commonly prescribed drugs, and they are generally well tolerated. However, several immediate and delayed hypersensitivity reactions due to PPIs have been reported. Objective: To review the clinical characteristics and management of immune-mediated immediate and delayed hypersensitivity reactions to PPIs. Methods: We performed a search of a medical literature data base from January 1980 to October 2019 by using keywords that included “proton-pump inhibitors” and “hypersensitivity.” Results: Anaphylaxis is the most-common clinical presentation in patients with immediate hypersensitivity reactions to PPIs, followed by urticaria and/or angioedema. Occupational contact dermatitis, maculopapular eruption, fixed drug eruption, symmetrical drug-related intertriginous and flexural exanthema, and severe cutaneous adverse reactions, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis have also been reported with PPIs. Conclusion: The current knowledge and severity of the reported reactions indicated the importance of consideration of a causal relationship between hypersensitivity reactions and PPIs, and awareness of the existence of cross-reactivity among PPIs.

scholarly journals Meropenem-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with known type IV penicillin hypersensitivity

2019 ◽  
Vol 12 (8) ◽  
pp. e230144 ◽  
Author(s):  
Muhammad Sameed ◽  
Christine Nwaiser ◽  
Prashant Bhandari ◽  
Sarah A Schmalzle
Keyword(s):  
Toxic Epidermal Necrolysis ◽  
Cross Reactivity ◽  
Delayed Hypersensitivity ◽  
Stevens Johnson Syndrome ◽  
Hypersensitivity Reactions ◽  
Beta Lactam ◽  
Type Iv ◽  
Johnson Syndrome ◽  
Life Threatening ◽  
History Of

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are considered variants of a disease continuum that results in a life-threatening exfoliative mucocutaneous disease. These are categorised as type IV cell-mediated delayed hypersensitivity reactions, and antibiotics are often implicated as a cause. Penicillins and other beta-lactam antibiotics are known to cause both immediate and delayed hypersensitivity reactions. While immediate IgE-mediated cross-reactivity between penicillins and carbapenems is well studied, less information on the risk of type IV delayed cell-mediated cross-reactivity between the two is available. We present a case of meropenem-induced SJS in a patient with documented history of SJS from amoxicillin. There are few cases of cross-reactivity with carbapenems reported in the literature, but based on the potential for life-threatening reaction, it is likely prudent to avoid the use of any beta-lactams in a patient with a history of SJS, TEN or any other severe cutaneous adverse reactions to another beta-lactam antibiotic.

Immediate-type hypersensitivity reactions to proton pump inhibitors: usefulness of skin tests in the diagnosis and assessment of cross-reactivity

Allergy ◽  
2013 ◽  
Vol 68 (8) ◽  
pp. 1008-1014 ◽  
Author(s):  
S. Kepil Özdemir ◽  
İ. Yılmaz ◽  
Ö. Aydın ◽  
S. Büyüköztürk ◽  
A. Gelincik ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Cross Reactivity ◽  
Skin Tests ◽  
Hypersensitivity Reactions

Analysis of the factors associated with diagnostic skin test positivity in immediate-type hypersensitivity reactions due to proton pump inhibitors

Allergy ◽  
2019 ◽  
Vol 74 (6) ◽  
pp. 1187-1190 ◽  
Author(s):  
Seçil Kepil Özdemir ◽  
Aslı Gelincik ◽  
Nail Paksoy ◽  
Gözde Köycü Buhari ◽  
Ferda Öner Erkekol ◽  
...  
Keyword(s):  
Skin Test ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Hypersensitivity Reactions ◽  
Factors Associated

Anaphylaxis to omeprazole. Cross-reactivity with the other proton pump inhibitors

2011 ◽  
Vol 39 (1) ◽  
pp. 54 ◽  
Author(s):  
P. Rojas Pérez-Ezquerra ◽  
L. Sánchez Morillas ◽  
J.J. Laguna Martínez ◽  
G. Davila Fernández ◽  
M. del Prado Gomez-Tembleque ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Cross Reactivity ◽  
The Other

Is the Use of Proton-pump Inhibitors a Risk Factor for Alzheimer’s Disease? Molecular Mechanisms and Clinical Implications

2018 ◽  
Vol 25 (18) ◽  
pp. 2166-2174 ◽  
Author(s):  
Kazuki Ide ◽  
Norihiro Matsuoka ◽  
Koji Kawakami
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Risk Factor ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Clinical Studies ◽  
Molecular Mechanisms ◽  
Current Knowledge ◽  
In Vivo Studies ◽  
Clinical Implications

Proton-pump inhibitors (PPIs), such as omeprazole, lansoprazole and rabeprazole, are used for the treatment of gastroesophageal reflux disease and peptic ulcer disease. The use of PPIs has increased, especially in older individuals, and a pharmacoepidemiological study indicated the use of PPIs peaks in people aged 80 years or older. In this population, Alzheimer's disease (AD) is a common neurological disorder and type of dementia, occurring with a frequency of approximately 10%. Currently, over 45 million people are estimated to have dementia worldwide, and it is a major cause of death in the elderly. Recent clinical studies have indicated that chronic use of PPIs can be a risk factor for increased incidence of dementia, including AD. Potential molecular mechanisms related to the pathophysiology of AD (e.g., modulation of amyloid protein processing) have also been reported in both in vitro and in vivo studies. Although the clinical implications of these results are inconclusive, a literature review of the current knowledge is important for future basic and clinical research. This review summarizes the possible mechanisms connecting the use of PPIs and the incidence of AD. Additionally, we summarize results from clinical studies to highlight the influence in humans.

IgE mediated anaphylactic reaction to omeprazole. Cross reactivity among Proton-Pump Inhibitors

2007 ◽  
Vol &NA; ◽  
pp. S267-S268
Author(s):  
Efthalia Stefanaki ◽  
Vasilios Vovolis ◽  
Ioanna Letsa ◽  
Nikolaos Koutsostathis
Keyword(s):  
Anaphylactic Reaction ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Cross Reactivity ◽  
Ige Mediated

Delayed-type hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro T-cell reactivity study

Allergy ◽  
2017 ◽  
Vol 73 (1) ◽  
pp. 221-229 ◽  
Author(s):  
C.-y. Lin ◽  
C.-W. Wang ◽  
C.-Y. R. Hui ◽  
Y.-C. Chang ◽  
C.-H. Yang ◽  
...  
Keyword(s):  
T Cell ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Delayed Type Hypersensitivity ◽  
Hypersensitivity Reactions ◽  
Cell Reactivity ◽  
T Cell Reactivity ◽  
Reactivity Study
Sign in / Sign up

Export Citation Format

Share Document